Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference
Pulmonx (NASDAQ:LUNG), a company specializing in minimally invasive lung disease treatments, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmonx (NASDAQ:LUNG), a company specializing in minimally invasive lung disease treatments, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for August 12, 2025, at 7:00 AM PT / 10:00 AM ET in Boston.
Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Pulmonx's website at investors.pulmonx.com.
Details
News Market Reaction – LUNG
The recorded move for LUNG in the trading session of this news was +1.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord Genuity 45th Annual Growth Conference in Boston on Tuesday, August 12, 2025, at 7:00 AM PT / 10:00 AM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraXTM Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraXTM is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.